Femasys (FEMY) to Release Quarterly Earnings on Thursday

Femasys (NASDAQ:FEMY) is expected to issue its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.0833) per share and revenue of $1.06 million for the quarter.

Femasys Price Performance

NASDAQ FEMY opened at $0.60 on Thursday. The company has a 50-day moving average price of $0.56 and a 200-day moving average price of $0.63. Femasys has a 52 week low of $0.31 and a 52 week high of $1.76. The company has a quick ratio of 0.61, a current ratio of 1.16 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $35.09 million, a P/E ratio of -0.83 and a beta of -2.53.

Institutional Trading of Femasys

Several institutional investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in Femasys in the 2nd quarter worth approximately $82,000. Osaic Holdings Inc. purchased a new stake in Femasys during the 2nd quarter valued at approximately $45,000. Geode Capital Management LLC raised its position in shares of Femasys by 50.8% during the fourth quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after buying an additional 131,052 shares during the last quarter. Kovack Advisors Inc. purchased a new position in shares of Femasys in the fourth quarter worth $27,000. Finally, Banco BTG Pactual S.A. purchased a new position in shares of Femasys in the fourth quarter worth $88,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on FEMY shares. Laidlaw initiated coverage on shares of Femasys in a research report on Thursday, November 20th. They set a “buy” rating and a $6.50 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Femasys in a research note on Thursday, January 22nd. Lake Street Capital assumed coverage on shares of Femasys in a research report on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price objective for the company. Finally, Wall Street Zen upgraded Femasys from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.